+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Evonik Industries AG (EVK) - Financial and Strategic SWOT Analysis Review

Evonik Industries AG (EVK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Evonik Industries AG (Evonik) is a company engaged in the development and production of specialty chemicals. The company's main activities include providing advanced technologies, custom solutions, and infrastructure services. Evonik's major products encompass high-performance polymers, crosslinkers, hydrogen peroxide, silicas, and additives for animal nutrition, and customized solutions like additives for coatings, adhesives, and pharmaceutical ingredients. The company serves a diverse range of industries including automotive, electronics, cosmetics, pharmaceuticals, and construction, offering products for applications such as coatings, lubricants, and medical devices. Evonik operates through a network of sites located in Germany, Slovakia, the USA, China, Singapore, Belgium, Austria, and Japan, targeting global markets. Evonik is headquartered in Essen, North Rhine-Westphalia, Germany.

Evonik Industries AG Key Recent Developments

  • Jun 10, 2026: More Cost-Efficient Green Hydrogen: Evonik Launches Pilot Plant for High-Performance Membrane
  • Jun 08, 2026: Directors’ Dealings - Evonik Industries AG: Lauren Kjeldsen Buys
  • May 26, 2026: Evonik Partners With University of Guanajuato to Advance Sustainable Mining Chemistry
  • May 12, 2026: AKROS Energy Inaugurates Pilot Plant for Salt-Based Hydrogen Storage

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Grunenthal GmbH - Key Facts
  • Grunenthal GmbH - Key Employees
  • Grunenthal GmbH - Key Employee Biographies
  • Grunenthal GmbH - Major Products and Services
  • Grunenthal GmbH - History
  • Grunenthal GmbH - Company Statement
  • Grunenthal GmbH - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Grunenthal GmbH - Business Description
  • Geographical Segment: Asia/Africa/Australia
  • Performance
  • Geographical Segment: Germany
  • Performance
  • Geographical Segment: Latin America
  • Performance
  • Geographical Segment: Rest of Europe
  • Performance
  • Geographical Segment: USA & Canada
  • Performance
  • R&D Overview
  • Grunenthal GmbH - SWOT Analysis
  • SWOT Analysis - Overview
  • Grunenthal GmbH - Strengths
  • Grunenthal GmbH - Weaknesses
  • Grunenthal GmbH - Opportunities
  • Grunenthal GmbH - Threats
  • Grunenthal GmbH - Key Competitors
Section 3 - Company’s Lifesciences Financial Deals and Alliances
  • Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
  • Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026
  • Grunenthal GmbH, Recent Deals Summary
Section 4 - Company’s Recent Developments
  • Mar 27, 2026: Grünenthal Achieves Strong Financial Results in 2025 Through Strategic Growth and Diversification
  • Mar 05, 2026: Grünenthal Licenses Exclusive South Korean Rights to Qutenza to BCWorld Pharm
  • Feb 24, 2026: Grünenthal Licenses Exclusive Australian Rights for Qutenza to Clinect
  • Feb 18, 2026: Grünenthal's NaV 1.8 Inhibitor Enters Clinical Development
  • Feb 06, 2026: Apotex and Grünenthal sign deal for Nebido Canadian distribution
  • Mar 27, 2025: Grunenthal : 2024 Financial Results
  • Jan 09, 2025: Grunenthal Appoints Prof. Dr. Uli Brödl as Chief Scientific Officer
Section 5 - Appendix
  • Methodology
  • About the Analyst
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Grunenthal GmbH, Key Facts
  • Grunenthal GmbH, Key Employees
  • Grunenthal GmbH, Key Employee Biographies
  • Grunenthal GmbH, Major Products and Services
  • Grunenthal GmbH, History
  • Grunenthal GmbH, Subsidiaries
  • Grunenthal GmbH, Key Competitors
  • Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
  • Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026
  • Grunenthal GmbH, Recent Deals Summary
List of Figures
  • Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
  • Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2020 to YTD 2026